Chairman of the Board

Stan Lapidus is an inventor/entrepreneur who serves on a number of healthcare and medical technology boards. He’s been founding CEO of four medical technology companies including Cytyc Corp (modern pap smear), Exact Sciences (non-invasive screening for colorectal cancer), Helicos (single molecule DNA sequencing) and SynapDx (early detection of autism).

Stan holds 36 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer.

Stan graduated from Cooper Union in New York City with a BS degree in electrical engineering.

Board Director

Amy is a highly respected leader in biotech and pharma. She joined Polaris Partners in 2014 and brings her commercial expertise to the startup biotech community. She is currently Partner of the LS Polaris Innovation Fund and is the active CEO and Co-Founder of Lyndra. She is also a Director of Quentis and Kallyope. Previously, Amy was General Counsel at Pfizer, President of Pfizer Nutrition, and President of Pfizer Consumer Healthcare. She has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Boards of Alnylam, Blue Buffalo, Ironwood, and the Whitehead Institute. She was Phi Beta Kappa at Wesleyan and earned her J.D. from Yale Law School.

Board Director

Theresia co-founded Aspect Ventures, a leading early-stage venture firm with a unique focus on bridging the funding gap between angels and the larger multi-stage VC platforms through collaboration and diversity. She led the firm’s early investments in Cato Networks, Deserve, Exabeam, ForeScout (FSCT), The Muse, Crew and ShieldX. Prior to launching Aspect, Theresia was a Managing General Partner at Accel where she championed many successful companies through IPOs or acquisitions including Imperva (IMPV), Trulia (TRLA), LearnVest (Northwestern Mutual), Jasper Design (CDNS) and Kosmix (WMT). Earlier, she worked at Release Software, Bain & Company and Silicon Graphics. Theresia holds an ScB in Engineering magna cum laude from Brown University (where she serves as Treasurer of Brown’s Corporation board) and an MBA from Stanford. Theresia has been honored seven times as a member of Forbes’ Midas List of top venture capitalists.

Board Director

Francis Cuss is a physician-scientist with broad experience in pharmaceutical research, clinical development and executive management during a career spanning more than 30 years with BMS, Schering-Plough and Glaxo. Francis retired from BMS as Executive Vice President, Chief Scientific Officer and Head of R&D. Francis has led highly productive discovery organizations which produced a pipeline of innovative medicines from in-house and external programs, helping numerous patients prevail against serious disease, and laying the foundation for significant company growth. He holds medical degrees from Cambridge University, U.K. and is a fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He is a member of the board of directors of Novo Holdings A/S, Denmark and Rubius Therapeutics, and Vice Chair of the Board of Trustees of Montclair State University, NJ. He has published numerous articles and book chapters on topics of medical interest and organizational effectiveness.

Board Director

Robert S. Langer is one of 10 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member. Dr. Langer has written more than 1,400 articles. He also has over 1,300 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history (h-index 262 with over 275,000 citations according to Google Scholar). He has received over 220 major awards. He is one of four living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world’s largest technology prize; the 2012 Priestley Medal, the highest award of the American Chemical Society; the 2013 Wolf Prize in Chemistry; the 2014 Breakthrough Prize in Life Sciences; and the 2014 Kyoto Prize.